ILMN Jun 2023 760.000 put
| Previous close | 519.50 |
| Open | N/A |
| Bid | 568.10 |
| Ask | 576.50 |
| Strike | 760.00 |
| Expiry date | 2023-06-16 |
| Day's range | 447.00 - 519.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Financial Times
Illumina accused by Brussels of ‘delay tactics’ on Grail divestiture
Brussels has accused Illumina of using “delay tactics” to prevent a speedy ruling on whether the world’s biggest gene sequencing company should be forced to divest cancer test developer Grail. It follows repeated claims by Illumina that it is moving as “expeditiously as possible” to resolve litigation linked to its $8bn acquisition of Grail, which is the focus of a bruising proxy battle waged by Carl Icahn, the veteran activist investor. US antitrust regulators also ordered Grail’s divestiture in April, a decision Illumina is appealing against.
Simply Wall St.12% Of This Illumina Insider's Holdings Were Sold \
Insiders were net sellers of Illumina, Inc.'s ( NASDAQ:ILMN ) stock during the past year. That is, insiders sold more...
- Financial Times
Why Vice’s bankruptcy is a warning on private equity investment
Plus, the battle heats up between Icahn and Illumina and Cayman Islands defends itself as a go-to for the super-rich
- Financial Times
Illumina chair ousted in proxy battle with Carl Icahn
Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years
BloombergIcahn Wins One Board Seat in Illumina Proxy Fight
(Bloomberg) -- Illumina Inc. shareholders voted to elect a board member nominated by activist shareholder Carl Icahn, a much-needed partial victory for the billionaire as his investment firm grapples with an attack by short-seller Hindenburg Research. Most Read from BloombergCathie Wood’s ARKK Dumped Nvidia Stock Before $560 Billion SurgeApple Plans to Turn Locked iPhones Into Smart Displays With iOS 17JPMorgan Tells 1,000 First Republic Employees They'll Lose Their JobsFirst Republic’s $35 Mill
- Financial Times
Illumina can survive loss of chair and CEO, says biotech group’s board director
Illumina is strong enough to survive the loss of its chair John Thompson and chief executive Francis deSouza if shareholders vote them down at an annual meeting on Thursday, a director of the company has said. Gary Guthart told the Financial Times there was depth on the board and management of the world’s biggest gene sequencing company beyond the two executives, who had been targeted in a proxy battle waged by activist investor Carl Icahn.
- Simply Wall St.
Does Illumina (NASDAQ:ILMN) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
ZacksIllumina (ILMN) Progresses in Pathogen Genomic Technologies
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
- Financial Times
Quick blood tests to spot cancer: will they help or harm patients?
Investors are pouring billions into companies claiming they can analyse DNA to find the disease early. But some scientists question if they really work
- Simply Wall St.
What Is Illumina, Inc.'s (NASDAQ:ILMN) Share Price Doing?
Let's talk about the popular Illumina, Inc. ( NASDAQ:ILMN ). The company's shares received a lot of attention from a...
- Simply Wall St.
Illumina (NASDAQ:ILMN) shareholders are up 6.6% this past week, but still in the red over the last three years
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...
- Simply Wall St.
Is Illumina, Inc. (NASDAQ:ILMN) Worth US$200 Based On Its Intrinsic Value?
Key Insights Illumina's estimated fair value is US$164 based on 2 Stage Free Cash Flow to Equity Illumina is estimated...
Motley FoolBetter Gene Sequencing Stock: Illumina vs. Bionano Genomics
Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).
Motley FoolWhy Illumina Fell 11.6% in April
The gene-sequencing company reported weaker results while the Federal Trade Commission has ordered it to divest its Grail acquisition.
ZacksIllumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
ZacksIllumina (ILMN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksIllumina (ILMN) Beats Q1 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksEXEL or ILMN: Which Is the Better Value Stock Right Now?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
ZacksTarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Motley FoolHere's Why You Shouldn't Buy the Dip With Illumina Stock
For example, over the last five years, Illumina's (NASDAQ: ILMN) stock is down nearly 5%. For those who aren't familiar, Illumina is the undisputed king of the gene sequencer hardware market, to where many accept it as a quasi-monopoly. When healthcare systems or research laboratories need to analyze genetic material, the company's devices are the industry's standard, and it has a product in every segment of the market.
ZacksIllumina (ILMN) Partners With Henry Ford Health for NGS Test
Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.
- Simply Wall St.
Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?
Illumina, Inc. ( NASDAQ:ILMN ) saw a double-digit share price rise of over 10% in the past couple of months on the...
Motley FoolIs There Any Hope for Illumina Stock?
With shares of Illumina (NASDAQ: ILMN) down 37% over the last 12 months and underperforming the market over the last five years, shareholders have had a rough time. As of April 3, regulators in the U.S. were rebuffing its acquisition of Grail, a cancer-testing company that it originally founded and spun off. While some competitors make devices that do the same thing as Illumina's products, there's certainly no rising star anywhere in sight that could take its place.
ZacksIllumina (ILMN) to Expand Genomics Capacity With New Pact
Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.
ZacksIllumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone
Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.